The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)



Gene Review

ATF7IP  -  activating transcription factor 7...

Homo sapiens

Synonyms: AM, ATF-IP, ATF-interacting protein, ATF7-interacting protein, ATFa-associated modulator, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of ATF7IP

  • Altered MCAF expression can therefore enhance the ability of activated monocytes to kill brain tumor cells [1].
  • Cachexia-inducing adenocarcinoma cells (cell line colon 26, clone 20) were transfected with either a control plasmid or MCAF expression vector [2].
  • To evaluate the effect of monocyte chemotactic and activating factor (MCAF/MCP-1/JE) on tumor progression and metastasis [2].
  • We report the novel finding that psoriasis has strong positive immunostaining for MCAF located to all the layers of the epidermis, except the stratum granulosum, in pustular, guttate and chronic plaque psoriasis [3].
  • Preincubation of basophils with pertussis toxin markedly diminished the basophil response to either RANTES or MCAF/MCP-1 [4].

High impact information on ATF7IP

  • Recombinant monocyte chemotactic-activating factor (MCAF) has been shown to induce histamine release from human basophils with a dose response between 10(-9) and 10(-6) M [5].
  • However, interleukin 3 (IL-3) and IL-5 could each prime basophils for MCAF-induced secretion [5].
  • At a suboptimal concentration (2.5 x 10(-9) M), MCAF was unable to prime the basophil to histamine release by other secretagogues [5].
  • Our findings suggest that MCAF may contribute to the accumulation of macrophages in inflamed rheumatoid joints [6].
  • These results suggest that RANTES and MCAF/MCP-1: 1) are potent activators of basophils; 2) may function via the same, or a closely related, receptor system in basophils; and 3) may represent a link between activation of monocytes, lymphocytes, and basophils in inflammatory disorders such as the late phase allergic reaction [4].

Biological context of ATF7IP


Anatomical context of ATF7IP


Associations of ATF7IP with chemical compounds

  • Urinary MCAF levels in the patients with active lesions were significantly higher than those with inactive lesions (20.3 +/- 6.4 vs. 1.7 +/- 0.3 pg/ml . creatinine, P < 0.01) [12].
  • Incubation with cycloheximide did not block the rapid reappearance of MCAF receptors within 20 min on the cell surface indicative of receptor recycling rather than new protein synthesis [8].
  • Northern blot analysis using enzyme inhibitors showed that phospholipase C, protein kinase C, and tyrosine kinase were involved in the stretch-induced gene expression of IL-8 and MCAF/MCP-1, whereas cAMP- or cGMP-dependent protein kinase was not [13].
  • Monocytes stimulated with PPD or M. tuberculosis expressed low levels of antigenic interleukin-8 but high levels of MCAF/MCP-1 compared with monocytes stimulated with lipopolysaccharide [14].
  • These findings suggest that MCAF, alone or in concert with other cytokines, primes monocytes for enhanced release of 02-, and that MCAF- or FMLP-induced intracellular acidification and alkalinization are closely associated with an increase in [Ca2+]i, but not O2- release [15].

Regulatory relationships of ATF7IP


Analytical, diagnostic and therapeutic context of ATF7IP

  • The levels of MCAF/MCP1 (mean +/- S.E.M.) were 107 +/- 15.8 pg/ml in patients with AA, 393.4 +/- 105.9 pg/ml in CHB and 36.4 +/- 10.9 pg/ml in the control group (P < 0.05) [17].
  • The aim of the current study was to examine associations among MCAF/MCP1 and bronchoalveolar lavage fluid (BALF) cells and disease severity as measured by airway caliber and bronchial hyperresponsiveness in patients with AA and CHB [17].
  • METHODS: Plasma levels of MCAF were determined by ELISA [7].
  • IL-1-treated HEC expressed high levels of MCAF/MCP-1/TDCF mRNA transcripts, as assessed by Northern blot analysis [18].
  • The purified MCAF showed microheterogeneity yielding two bands on SDS-PAGE analysis [19].


  1. Altered monocyte chemotactic and activating factor gene expression in human glioblastoma cell lines increased their susceptibility to cytotoxicity. Asano, T., An, T., Jia, S.F., Kleinerman, E.S. J. Leukoc. Biol. (1996) [Pubmed]
  2. Human MCAF gene transfer enhances the metastatic capacity of a mouse cachectic adenocarcinoma cell line in vivo. Nakashima, E., Mukaida, N., Kubota, Y., Kuno, K., Yasumoto, K., Ichimura, F., Nakanishi, I., Miyasaka, M., Matsushima, K. Pharm. Res. (1995) [Pubmed]
  3. Localization of monocyte chemotactic and activating factor (MCAF/MCP-1) in psoriasis. Deleuran, M., Buhl, L., Ellingsen, T., Harada, A., Larsen, C.G., Matsushima, K., Deleuran, B. J. Dermatol. Sci. (1996) [Pubmed]
  4. RANTES, a monocyte and T lymphocyte chemotactic cytokine releases histamine from human basophils. Kuna, P., Reddigari, S.R., Schall, T.J., Rucinski, D., Viksman, M.Y., Kaplan, A.P. J. Immunol. (1992) [Pubmed]
  5. Monocyte chemotactic and activating factor is a potent histamine-releasing factor for human basophils. Kuna, P., Reddigari, S.R., Rucinski, D., Oppenheim, J.J., Kaplan, A.P. J. Exp. Med. (1992) [Pubmed]
  6. Expression of monocyte chemotactic and activating factor in rheumatoid arthritis. Regulation of its production in synovial cells by interleukin-1 and tumor necrosis factor. Akahoshi, T., Wada, C., Endo, H., Hirota, K., Hosaka, S., Takagishi, K., Kondo, H., Kashiwazaki, S., Matsushima, K. Arthritis Rheum. (1993) [Pubmed]
  7. In-vivo induction of monocyte chemotactic and activating factor in patients with chronic renal failure. Akahoshi, T., Kobayashi, N., Hosaka, S., Sekiyama, N., Wada, C., Kondo, H. Nephrol. Dial. Transplant. (1995) [Pubmed]
  8. Studies of binding and internalization of human recombinant monocyte chemotactic and activating factor (MCAF) by monocytic cells. Wang, J.M., Hishinuma, A., Oppenheim, J.J., Matsushima, K. Cytokine (1993) [Pubmed]
  9. Monocyte chemotaxis and activating factor production by keratinocytes in response to IFN-gamma. Barker, J.N., Jones, M.L., Swenson, C.L., Sarma, V., Mitra, R.S., Ward, P.A., Johnson, K.J., Fantone, J.C., Dixit, V.M., Nickoloff, B.J. J. Immunol. (1991) [Pubmed]
  10. Synergistic antitumor interaction of human monocyte chemotactant protein-1 gene transfer and modulator for tumor-infiltrating macrophages. Nakashima, E., Kubota, Y., Matsushita, R., Ozaki, E., Ichimura, F., Kawahara, S., Nakanishi, I., Kuno, K., Matsushima, K. Pharm. Res. (1998) [Pubmed]
  11. Monocyte chemotactic and activating factor/monocyte chemoattractant protein-1-mediated histamine release from human nasal mucosa. Fujikura, T., Otsuka, H. Arch. Otolaryngol. Head Neck Surg. (1998) [Pubmed]
  12. Monitoring urinary levels of monocyte chemotactic and activating factor reflects disease activity of lupus nephritis. Wada, T., Yokoyama, H., Su, S.B., Mukaida, N., Iwano, M., Dohi, K., Takahashi, Y., Sasaki, T., Furuichi, K., Segawa, C., Hisada, Y., Ohta, S., Takasawa, K., Kobayashi, K., Matsushima, K. Kidney Int. (1996) [Pubmed]
  13. Cyclic stretch upregulates production of interleukin-8 and monocyte chemotactic and activating factor/monocyte chemoattractant protein-1 in human endothelial cells. Okada, M., Matsumori, A., Ono, K., Furukawa, Y., Shioi, T., Iwasaki, A., Matsushima, K., Sasayama, S. Arterioscler. Thromb. Vasc. Biol. (1998) [Pubmed]
  14. Selective expression of monocyte chemotactic and activating factor/monocyte chemoattractant protein 1 in human blood monocytes by Mycobacterium tuberculosis. Kasahara, K., Tobe, T., Tomita, M., Mukaida, N., Shao-Bo, S., Matsushima, K., Yoshida, T., Sugihara, S., Kobayashi, K. J. Infect. Dis. (1994) [Pubmed]
  15. Activation and priming of human monocytes by monocyte chemotactic activating factor: cooperation with other inflammatory cytokines and close association between an increase in cytoplasmic free Ca2+ and intracellular acidification. Azuma, E.K., Yuo, A., Matsushima, T., Kasahara, T., Mizoguchi, H., Saito, M., Takaku, F., Kitagawa, S. Exp. Hematol. (1996) [Pubmed]
  16. MCAF1/AM is involved in Sp1-mediated maintenance of cancer-associated telomerase activity. Liu, L., Ishihara, K., Ichimura, T., Fujita, N., Hino, S., Tomita, S., Watanabe, S., Saitoh, N., Ito, T., Nakao, M. J. Biol. Chem. (2009) [Pubmed]
  17. Monocyte chemotactic and activating factor/monocyte chemoattractant protein in bronchoalveolar lavage fluid from patients with atopic asthma and chronic bronchitis. Relationship to lung function tests, bronchial hyper-responsiveness and cytology of bronchoalveolar lavage fluid. Rózyk, K.J., Płusa, T., Kuna, P., Pirozyńska, E. Immunol. Lett. (1997) [Pubmed]
  18. Monocyte chemotactic and activating factor gene expression induced in endothelial cells by IL-1 and tumor necrosis factor. Sica, A., Wang, J.M., Colotta, F., Dejana, E., Mantovani, A., Oppenheim, J.J., Larsen, C.G., Zachariae, C.O., Matsushima, K. J. Immunol. (1990) [Pubmed]
  19. Properties of monocyte chemotactic and activating factor (MCAF) purified from a human fibrosarcoma cell line. Zachariae, C.O., Anderson, A.O., Thompson, H.L., Appella, E., Mantovani, A., Oppenheim, J.J., Matsushima, K. J. Exp. Med. (1990) [Pubmed]
WikiGenes - Universities